Vanda Non Currrent Assets Other vs Common Stock Shares Outstanding Analysis

VNDA Stock

USD 4.42 0.28 5.96%

Vanda Pharmaceuticals financial indicator trend analysis is much more than just breaking down Vanda Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Vanda Pharmaceuticals is a good investment. Please check the relationship between Vanda Pharmaceuticals Non Currrent Assets Other and its Common Stock Shares Outstanding accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vanda Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.

For information on how to trade Vanda Stock refer to our How to Trade Vanda Stock guide.

Non Currrent Assets Other vs Common Stock Shares Outstanding

Non Currrent Assets Other vs Common Stock Shares Outstanding Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Vanda Pharmaceuticals Non Currrent Assets Other account and Common Stock Shares Outstanding. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between Vanda Pharmaceuticals' Non Currrent Assets Other and Common Stock Shares Outstanding is -0.24. Overlapping area represents the amount of variation of Non Currrent Assets Other that can explain the historical movement of Common Stock Shares Outstanding in the same time period over historical financial statements of Vanda Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Vanda Pharmaceuticals' Non Currrent Assets Other and Common Stock Shares Outstanding is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Non Currrent Assets Other of Vanda Pharmaceuticals are associated (or correlated) with its Common Stock Shares Outstanding. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Common Stock Shares Outstanding has no effect on the direction of Non Currrent Assets Other i.e., Vanda Pharmaceuticals' Non Currrent Assets Other and Common Stock Shares Outstanding go up and down completely randomly.

Correlation Coefficient

-0.24

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Non Currrent Assets Other

Assets that are not physical or tangible, expected to provide value for more than one year, and not easily converted into cash, such as long-term investments or patents.

Common Stock Shares Outstanding

The total number of shares of a company's common stock that are currently owned by all its shareholders.

Most indicators from Vanda Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Vanda Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vanda Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.

For information on how to trade Vanda Stock refer to our How to Trade Vanda Stock guide.At present, Vanda Pharmaceuticals' Tax Provision is projected to increase significantly based on the last few years of reporting. The current year's Sales General And Administrative To Revenue is expected to grow to 1.03, whereas Selling General Administrative is forecasted to decline to about 75.8 M.

	2022	2023	2024	2025 (projected)
Gross Profit	230.1M	192.6M	221.5M	123.7M
Total Revenue	254.4M	192.6M	221.5M	137.0M

Gross Profit Total Revenue

Vanda Pharmaceuticals fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Common Stock
Total Assets		0.07	0.94	0.91	0.99	-0.46	0.73	-0.51	-0.58	0.44	0.04	0.74	0.94	0.95	0.95	0.98	0.74	-0.31	-0.36	0.63	0.78	0.33	0.89	0.99	-0.43	0.75
Short Long Term Debt Total	0.07		0.07	0.18	0.01	0.28	0.2	0.13	-0.13	-0.77	0.25	0.06	-0.05	-0.02	-0.03	0.13	0.58	-0.92	0.3	0.21	0.5	0.46	-0.11	0.13	0.34	0.56
Other Current Liab	0.94	0.07		0.95	0.95	-0.6	0.73	-0.69	-0.43	0.32	0.32	0.6	0.88	0.95	0.87	0.92	0.77	-0.28	-0.53	0.68	0.8	0.22	0.86	0.94	-0.22	0.78
Total Current Liabilities	0.91	0.18	0.95		0.87	-0.38	0.64	-0.51	-0.56	0.21	0.34	0.69	0.85	0.94	0.8	0.89	0.75	-0.41	-0.3	0.61	0.76	0.46	0.84	0.9	-0.1	0.76
Total Stockholder Equity	0.99	0.01	0.95	0.87		-0.58	0.76	-0.61	-0.51	0.48	0.06	0.67	0.93	0.93	0.95	0.97	0.73	-0.23	-0.49	0.64	0.78	0.19	0.88	0.97	-0.45	0.74
Other Liab	-0.46	0.28	-0.6	-0.38	-0.58		-0.53	0.92	-0.18	-0.35	-0.32	0.02	-0.43	-0.48	-0.48	-0.43	-0.41	-0.25	0.99	-0.44	-0.45	0.62	-0.44	-0.45	0.12	-0.42
Property Plant And Equipment Net	0.73	0.2	0.73	0.64	0.76	-0.53		-0.58	-0.07	0.31	0.01	0.19	0.6	0.6	0.84	0.76	0.75	-0.22	-0.43	0.77	0.78	0.15	0.54	0.77	-0.29	0.75
Current Deferred Revenue	-0.51	0.13	-0.69	-0.51	-0.61	0.92	-0.58		-0.12	-0.22	-0.52	-0.02	-0.47	-0.56	-0.49	-0.48	-0.54	-0.09	0.9	-0.55	-0.55	0.43	-0.47	-0.51	-0.09	-0.54
Net Debt	-0.58	-0.13	-0.43	-0.56	-0.51	-0.18	-0.07	-0.12		-0.21	0.04	-0.95	-0.59	-0.64	-0.43	-0.57	-0.36	0.39	-0.23	-0.06	-0.39	-0.61	-0.56	-0.55	0.35	-0.38
Retained Earnings	0.44	-0.77	0.32	0.21	0.48	-0.35	0.31	-0.22	-0.21		-0.47	0.33	0.5	0.43	0.58	0.41	-0.13	0.64	-0.29	0.11	-0.04	-0.14	0.46	0.39	-0.68	-0.12
Accounts Payable	0.04	0.25	0.32	0.34	0.06	-0.32	0.01	-0.52	0.04	-0.47		-0.06	-0.02	0.21	-0.14	0.04	0.36	-0.21	-0.38	0.25	0.32	-0.05	0.06	0.08	0.57	0.35
Cash	0.74	0.06	0.6	0.69	0.67	0.02	0.19	-0.02	-0.95	0.33	-0.06		0.77	0.77	0.61	0.7	0.4	-0.34	0.09	0.12	0.44	0.54	0.74	0.69	-0.4	0.42
Non Current Assets Total	0.94	-0.05	0.88	0.85	0.93	-0.43	0.6	-0.47	-0.59	0.5	-0.02	0.77		0.9	0.9	0.87	0.6	-0.21	-0.34	0.39	0.64	0.28	0.96	0.87	-0.38	0.62
Non Currrent Assets Other	0.95	-0.02	0.95	0.94	0.93	-0.48	0.6	-0.56	-0.64	0.43	0.21	0.77	0.9		0.85	0.92	0.67	-0.24	-0.4	0.57	0.71	0.31	0.87	0.93	-0.27	0.69
Other Assets	0.95	-0.03	0.87	0.8	0.95	-0.48	0.84	-0.49	-0.43	0.58	-0.14	0.61	0.9	0.85		0.93	0.64	-0.16	-0.37	0.61	0.69	0.25	0.84	0.93	-0.51	0.65
Cash And Short Term Investments	0.98	0.13	0.92	0.89	0.97	-0.43	0.76	-0.48	-0.57	0.41	0.04	0.7	0.87	0.92	0.93		0.76	-0.35	-0.33	0.71	0.8	0.35	0.81	1.0	-0.46	0.77
Common Stock Total Equity	0.74	0.58	0.77	0.75	0.73	-0.41	0.75	-0.54	-0.36	-0.13	0.36	0.4	0.6	0.67	0.64	0.76		-0.66	-0.34	0.73	0.99	0.32	0.56	0.77	-0.04	1.0
Common Stock Shares Outstanding	-0.31	-0.92	-0.28	-0.41	-0.23	-0.25	-0.22	-0.09	0.39	0.64	-0.21	-0.34	-0.21	-0.24	-0.16	-0.35	-0.66		-0.29	-0.3	-0.6	-0.59	-0.19	-0.35	-0.24	-0.66
Non Current Liabilities Total	-0.36	0.3	-0.53	-0.3	-0.49	0.99	-0.43	0.9	-0.23	-0.29	-0.38	0.09	-0.34	-0.4	-0.37	-0.33	-0.34	-0.29		-0.37	-0.37	0.68	-0.36	-0.35	0.05	-0.35
Other Current Assets	0.63	0.21	0.68	0.61	0.64	-0.44	0.77	-0.55	-0.06	0.11	0.25	0.12	0.39	0.57	0.61	0.71	0.73	-0.3	-0.37		0.74	0.18	0.43	0.72	-0.13	0.72
Other Stockholder Equity	0.78	0.5	0.8	0.76	0.78	-0.45	0.78	-0.55	-0.39	-0.04	0.32	0.44	0.64	0.71	0.69	0.8	0.99	-0.6	-0.37	0.74		0.32	0.6	0.81	-0.12	0.99
Total Liab	0.33	0.46	0.22	0.46	0.19	0.62	0.15	0.43	-0.61	-0.14	-0.05	0.54	0.28	0.31	0.25	0.35	0.32	-0.59	0.68	0.18	0.32		0.25	0.34	0.0	0.33
Property Plant And Equipment Gross	0.89	-0.11	0.86	0.84	0.88	-0.44	0.54	-0.47	-0.56	0.46	0.06	0.74	0.96	0.87	0.84	0.81	0.56	-0.19	-0.36	0.43	0.6	0.25		0.82	-0.33	0.58
Total Current Assets	0.99	0.13	0.94	0.9	0.97	-0.45	0.77	-0.51	-0.55	0.39	0.08	0.69	0.87	0.93	0.93	1.0	0.77	-0.35	-0.35	0.72	0.81	0.34	0.82		-0.44	0.78
Short Term Debt	-0.43	0.34	-0.22	-0.1	-0.45	0.12	-0.29	-0.09	0.35	-0.68	0.57	-0.4	-0.38	-0.27	-0.51	-0.46	-0.04	-0.24	0.05	-0.13	-0.12	0.0	-0.33	-0.44		-0.04
Common Stock	0.75	0.56	0.78	0.76	0.74	-0.42	0.75	-0.54	-0.38	-0.12	0.35	0.42	0.62	0.69	0.65	0.77	1.0	-0.66	-0.35	0.72	0.99	0.33	0.58	0.78	-0.04

Click cells to compare fundamentals

Vanda Pharmaceuticals Account Relationship Matchups

Vanda Pharmaceuticals fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	533.5M	593.8M	634.2M	648.4M	745.7M	783.0M
Short Long Term Debt Total	13.6M	10.1M	11.1M	9.4M	10.8M	9.0M
Other Current Liab	62.8M	71.2M	76.4M	78.2M	89.9M	94.4M
Total Current Liabilities	65.9M	74.4M	91.4M	87.7M	100.9M	105.9M
Total Stockholder Equity	453.3M	504.9M	527.2M	544.9M	626.6M	658.0M
Other Liab	843K	2.8M	4.4M	6.8M	6.1M	5.8M
Property Plant And Equipment Net	14.6M	12.4M	11.0M	9.1M	10.5M	5.4M
Net Debt	(47.4M)	(42.0M)	(123.9M)	(126.4M)	(113.8M)	(108.1M)
Retained Earnings	(197.3M)	(164.2M)	(157.9M)	(155.4M)	(139.9M)	(146.8M)
Accounts Payable	1.0M	925K	12.7M	7.1M	8.2M	6.4M
Cash	61.0M	52.1M	135.0M	135.8M	156.2M	164.0M
Non Current Assets Total	124.3M	115.5M	115.0M	215.5M	247.8M	260.2M
Non Currrent Assets Other	6.1M	7.6M	10.9M	10.0M	11.5M	12.1M
Other Assets	91.5M	88.2M	83.0M	85.4M	98.2M	103.1M
Cash And Short Term Investments	367.7M	432.8M	466.9M	388.3M	446.5M	468.8M
Common Stock Total Equity	54K	55K	56K	57K	65.6K	39.5K
Common Stock Shares Outstanding	55.2M	56.9M	57.0M	57.6M	51.8M	48.2M
Liabilities And Stockholders Equity	533.5M	593.8M	634.2M	648.4M	745.7M	783.0M
Non Current Liabilities Total	14.3M	14.4M	15.6M	15.8M	14.2M	13.5M
Other Current Assets	10.1M	24.0M	17.7M	9.2M	10.5M	7.5M
Other Stockholder Equity	650.3M	669.2M	686.2M	700.3M	805.3M	445.4M
Total Liab	80.2M	88.9M	107.0M	103.5M	119.1M	84.6M
Property Plant And Equipment Gross	4.1M	12.4M	11.0M	20.3M	23.4M	24.5M
Total Current Assets	409.1M	478.3M	519.3M	432.9M	497.9M	522.8M
Accumulated Other Comprehensive Income	239K	(175K)	(1.2M)	(30K)	(34.5K)	(36.2K)
Short Term Debt	2.1M	2.3M	2.3M	2.4M	2.2M	2.1M
Common Stock	55K	56K	57K	58K	66.7K	40.7K
Property Plant Equipment	3.9M	4.1M	12.4M	2.6M	3.0M	3.5M
Short Term Investments	306.7M	380.7M	331.8M	252.4M	290.3M	151.7M
Net Receivables	30.0M	32.5M	33.5M	34.2M	39.3M	41.2M
Inventory	1.3M	1.0M	1.2M	1.4M	1.6M	1.4M
Intangible Assets	21.6M	20.1M	18.6M	121.4M	139.6M	146.6M
Net Tangible Assets	387.9M	431.7M	484.8M	508.6M	584.9M	614.2M
Retained Earnings Total Equity	(220.7M)	(197.3M)	(164.2M)	(157.9M)	(181.6M)	(190.7M)
Capital Surpluse	631.3M	650.3M	669.2M	686.2M	789.2M	578.0M
Non Current Liabilities Other	14.3M	14.4M	15.6M	8.8M	10.2M	9.9M
Net Invested Capital	453.3M	504.9M	527.2M	544.9M	626.6M	447.6M
Net Working Capital	343.2M	403.9M	427.9M	345.2M	397.0M	339.5M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

CSX	CSX Corporation
ETON	Eton Pharmaceuticals
ALLT	Allot Communications

When determining whether Vanda Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Vanda Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Vanda Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Vanda Pharmaceuticals Stock:

How To Invest In Vanda

Details

Is Vanda Stock a good investment?

Details

What is Vanda Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vanda Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.

For information on how to trade Vanda Stock refer to our How to Trade Vanda Stock guide.

You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vanda Pharmaceuticals. If investors know Vanda will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vanda Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.96)

Earnings Share

(0.19)

Revenue Per Share

3.293

Quarterly Revenue Growth

0.228

Return On Assets

(0.04)

The market value of Vanda Pharmaceuticals is measured differently than its book value, which is the value of Vanda that is recorded on the company's balance sheet. Investors also form their own opinion of Vanda Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Vanda Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vanda Pharmaceuticals' market value can be influenced by many factors that don't directly affect Vanda Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Vanda Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Vanda Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vanda Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Vanda Non Currrent Assets Other vs Common Stock Shares Outstanding Analysis

Non Currrent Assets Other vs Common Stock Shares Outstanding

Non Currrent Assets Other vs Common Stock Shares Outstanding Correlation Analysis

Correlation Coefficient

Non Currrent Assets Other

Common Stock Shares Outstanding

Vanda Pharmaceuticals fundamental ratios Correlations

Vanda Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Vanda Pharmaceuticals fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Cash And Short Term Investments
Common Stock	+ 1.0	Common Stock Total Equity
Total Stockholder Equity	+ 0.99	Total Assets
Total Current Assets	+ 0.99	Total Assets
Non Current Liabilities Total	+ 0.99	Other Liab
Other Stockholder Equity	+ 0.99	Common Stock Total Equity

Cash	- 0.95	Net Debt
Common Stock Shares Outstanding	- 0.92	Short Long Term Debt Total
Retained Earnings	- 0.77	Short Long Term Debt Total
Current Deferred Revenue	- 0.69	Other Current Liab
Short Term Debt	- 0.68	Retained Earnings
Common Stock	- 0.66	Common Stock Shares Outstanding